<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p64" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_64{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_64{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_64{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_64{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_64{left:238px;bottom:1076px;letter-spacing:-0.01px;}
#t6_64{left:238px;bottom:1057px;letter-spacing:-0.01px;}
#t7_64{left:238px;bottom:1037px;letter-spacing:-0.01px;}
#t8_64{left:238px;bottom:1003px;letter-spacing:-0.01px;}
#t9_64{left:238px;bottom:983px;letter-spacing:-0.01px;}
#ta_64{left:238px;bottom:964px;letter-spacing:-0.01px;}
#tb_64{left:238px;bottom:944px;letter-spacing:-0.01px;}
#tc_64{left:238px;bottom:925px;letter-spacing:-0.01px;}
#td_64{left:238px;bottom:906px;letter-spacing:-0.01px;}
#te_64{left:238px;bottom:886px;letter-spacing:-0.01px;}
#tf_64{left:238px;bottom:867px;letter-spacing:-0.01px;}
#tg_64{left:238px;bottom:847px;letter-spacing:-0.01px;}
#th_64{left:238px;bottom:774px;letter-spacing:-0.01px;}
#ti_64{left:238px;bottom:754px;letter-spacing:-0.01px;}
#tj_64{left:238px;bottom:735px;letter-spacing:-0.01px;}
#tk_64{left:238px;bottom:715px;letter-spacing:-0.01px;}
#tl_64{left:238px;bottom:696px;letter-spacing:-0.01px;}
#tm_64{left:238px;bottom:677px;letter-spacing:-0.01px;}
#tn_64{left:238px;bottom:657px;letter-spacing:-0.01px;}
#to_64{left:238px;bottom:638px;letter-spacing:-0.01px;}
#tp_64{left:238px;bottom:618px;letter-spacing:-0.01px;}
#tq_64{left:238px;bottom:599px;letter-spacing:-0.01px;}
#tr_64{left:238px;bottom:579px;letter-spacing:-0.01px;}
#ts_64{left:238px;bottom:486px;letter-spacing:-0.01px;}
#tt_64{left:238px;bottom:467px;letter-spacing:-0.01px;}
#tu_64{left:238px;bottom:447px;letter-spacing:-0.01px;}
#tv_64{left:238px;bottom:393px;letter-spacing:-0.01px;}
#tw_64{left:238px;bottom:374px;letter-spacing:-0.01px;}
#tx_64{left:238px;bottom:354px;letter-spacing:-0.01px;}
#ty_64{left:238px;bottom:335px;letter-spacing:-0.01px;}
#tz_64{left:238px;bottom:316px;letter-spacing:-0.01px;}
#t10_64{left:238px;bottom:296px;letter-spacing:-0.01px;}
#t11_64{left:238px;bottom:277px;letter-spacing:-0.01px;}
#t12_64{left:238px;bottom:257px;letter-spacing:-0.01px;}
#t13_64{left:238px;bottom:238px;letter-spacing:-0.01px;}
#t14_64{left:238px;bottom:218px;letter-spacing:-0.01px;}
#t15_64{left:238px;bottom:199px;letter-spacing:-0.01px;}
#t16_64{left:238px;bottom:145px;letter-spacing:-0.01px;}
#t17_64{left:238px;bottom:125px;letter-spacing:-0.01px;}
#t18_64{left:238px;bottom:106px;letter-spacing:-0.01px;}
#t19_64{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_64{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_64{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_64{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts64" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg64Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg64" style="-webkit-user-select: none;"><object width="908" height="1286" data="64/64.svg" type="image/svg+xml" id="pdf64" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_64" class="t s0_64">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_64" class="t s1_64">64 </span>
<span id="t3_64" class="t s2_64">Area. Macroscopic tumors are irradiated with 70-72 Gy, the former tumor bed of the primary </span>
<span id="t4_64" class="t s2_64">tumor or affected lymph nodes in the adjuvant situation with 60-66 Gy (resection &lt;5mm; </span>
<span id="t5_64" class="t s2_64">glottis &lt;1mm) in healthy tissue and lymph nodes with extracapsular tumor growth: 64-66 Gy, </span>
<span id="t6_64" class="t s2_64">all other areas: 60 Gy) and potentially microscopically affected lymph node areas with 50-54 </span>
<span id="t7_64" class="t s2_64">Gy. </span>
<span id="t8_64" class="t s2_64">In primary radiation therapy in particular, therapy intensification through changes in the dose- </span>
<span id="t9_64" class="t s2_64">time concept (shortened total treatment time through acceleration, increasing the total dose </span>
<span id="ta_64" class="t s2_64">through hyperfractionation) has been tested in a series of randomized studies. The meta- </span>
<span id="tb_64" class="t s2_64">analysis [200] of these studies shows that a moderate shortening of the total treatment time </span>
<span id="tc_64" class="t s2_64">from 7 weeks to 5.5-6 weeks while maintaining the total dose leads to significantly improved </span>
<span id="td_64" class="t s2_64">locoregional tumor control, but no significant prolongation of overall survival. An even greater </span>
<span id="te_64" class="t s2_64">shortening of the total treatment time to a minimum of 12 days [211] was only feasible at the </span>
<span id="tf_64" class="t s2_64">expense of a significantly reduced total dose (54 Gy), but led to neither an improvement in </span>
<span id="tg_64" class="t s2_64">locoregional tumor control nor in survival. </span>
<span id="th_64" class="t s2_64">Pure hyperfractionation with escalation of the total dose to 74-80 Gy with 5x per week twice </span>
<span id="ti_64" class="t s2_64">daily irradiation with a single dose of 1.15 -1.20 Gy single dose resulted in a significant </span>
<span id="tj_64" class="t s2_64">improvement in both locoregional tumor control and overall survival compared to </span>
<span id="tk_64" class="t s2_64">conventionally fractionated radiotherapy (70 Gy in 7 weeks with 2 Gy single dose) [200]. Of 6515 </span>
<span id="tl_64" class="t s2_64">patients in the studies on acceleration and hyperfractionation, 2377 patients had laryngeal </span>
<span id="tm_64" class="t s2_64">carcinoma. In the subgroup analysis of the meta-analysis [200], no different effects depending </span>
<span id="tn_64" class="t s2_64">on tumor location could be found. HPV status was not investigated in any of these studies, most </span>
<span id="to_64" class="t s2_64">of which were conducted in the 1980s and 1990s, so the influence of HPV status on the effects </span>
<span id="tp_64" class="t s2_64">of different fractionations is unknown. From the observation that the effects in oropharyngeal </span>
<span id="tq_64" class="t s2_64">carcinomas, which are often HPV-positive, were no different than in laryngeal carcinomas, it can </span>
<span id="tr_64" class="t s2_64">be indirectly concluded that the influence of HPV status is probably small. </span>
<span id="ts_64" class="t s2_64">In almost all fractionation studies, the proportion of laryngeal carcinomas was small. </span>
<span id="tt_64" class="t s2_64">However, there is no reason to assume that the radiobiology of HPV neg. SCCs in the </span>
<span id="tu_64" class="t s2_64">larynx differs from other HPV neg. SCCs in the pharynx/oral cavity. </span>
<span id="tv_64" class="t s2_64">Whether accelerated radiotherapy is superior to conventionally fractionated radiotherapy, </span>
<span id="tw_64" class="t s2_64">even in combination with simultaneous chemotherapy, was investigated in two randomized </span>
<span id="tx_64" class="t s2_64">trials [193, 212], in which, however, only 6% and 25% of the patients had laryngeal carcinoma, </span>
<span id="ty_64" class="t s2_64">and 18% and 9% had hypopharyngeal carcinoma, respectively. Both studies found no benefit </span>
<span id="tz_64" class="t s2_64">of accelerated radiotherapy in combination with chemotherapy in any of the relevant </span>
<span id="t10_64" class="t s2_64">endpoints. However, in both studies, less chemotherapy was administered during </span>
<span id="t11_64" class="t s2_64">radiotherapy because the total treatment time in the accelerated arms was shortened by one </span>
<span id="t12_64" class="t s2_64">week. The toxicities of the treatments were approximately the same. Both treatment </span>
<span id="t13_64" class="t s2_64">regimens can therefore be regarded as equivalent standard therapies. The protocols for </span>
<span id="t14_64" class="t s2_64">simultaneous radiochemotherapy that are currently best supported by studies are listed </span>
<span id="t15_64" class="t s2_64">below. </span>
<span id="t16_64" class="t s2_64">In two smaller randomized trials [213, 214], purely hyperfractionated radiotherapy with dose </span>
<span id="t17_64" class="t s2_64">escalation to 74 or 80 Gy with or without simultaneous chemotherapy was investigated. In both </span>
<span id="t18_64" class="t s2_64">studies, the additional chemotherapy led to </span>
<span id="t19_64" class="t s0_64">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
